1Gianni AM, Berinstein NL, Evans PA, et al. Stem-cell transplantation in non-Hodgkin's lymphoma: improving outcome. Anticancer Drugs,2002,13 Suppl 2:35-42.
2Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma:a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin On
3Margolin KA, Negrin RS, Wong KK, et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy.Immunol Rev,1997,157:231-240.
4Hajek R, Koristek Z, Vinklarkova J, et al. Interleukin-2 activation of haematopoietic stem cells. Acta Med Austriaca, 2002,29:61-67.
5Margolin KA, van Besien K, Wright C, et al. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant, 1999,5:36-45.
6Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autol
7Lazzarino M, Arcaini L, Bemasconi P, et al A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells,high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cel
